
[EPISODE 20] Dr. David Johnson Talks Frosted Flakes, Small Molecules, and Pharmacokinetics!
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
The advanced laboratory facilities in Melbourne serve as our Australian headquarters, where we specialise in and are passionate about using cutting-edge thinking and technology to support the development of novel therapeutics, vaccines and diagnostics
We are Australia’s most comprehensive specialty laboratory for therapeutic, vaccine and diagnostics development. We develop and conduct pharmacokinetic (PK) and pharmacodynamic (PD) assays across a wide variety of therapeutic areas providing a one stop shop for all of your clinical trial requirements.
Australia is the jurisdiction of choice for conducting early phase clinical trials with three major advantages: Speed, Cost and Quality.
Speed: With the country’s fast and pragmatic regulatory environment for Phase 1 clinical studies, there is an average 4-6 weeks for review and approval for healthy volunteer studies due to IND not being required to conduct clinical trials in Australia.
Cost: The Australian government offers attractive R&D tax incentives including cash rebates to eligible companies. According to a cost comparison study, Australia is ~30% cheaper than the US before tax incentives; and 60% cheaper after tax incentives for conducting your clinical trials.
Quality: Australia is an OECD member resulting in mutual acceptance of data by global regulatory bodies. Data from studies conducted in Australia can be used to support international regulatory applications, including the US FDA and European Medicines Evaluation Agency (EMEA).
The advantages of Australia as an early phase location for clinical trials provides multiple options for our customers. Whether it’s starting your Phase 1 trial in Australia and transitioning to our global BioAgilytix team for Phase 2+ or choosing to conduct your clinical studies in the USA or Europe, BioAgilytix can provide a solution for all of your clinical requirements.
BioAgilytix has two locations in Australia to best serve the needs of our partners and customers.
Our Melbourne location is at the leading Burnet Institute, situated in one of Australia’s key biomedical and clinical research hubs and is co-located with Australia’s largest Phase 1 unit, which makes us well-positioned to support your clinical requirements. Our Melbourne location operates both BSL 2 and 3 laboratories.
Our Brisbane location is at the Translational Research Institute (TRI) within the Princess Alexandra Hospital. With its focus on effective translation of innovative medical research, the close physical and intellectual collaboration between academia, industry and clinicians facilitates BioAgilytix’s mission of enabling the breakthroughs of tomorrow today.
Our industry-experienced chemistry and biology teams enjoy the challenges of developing, validating and conducting sensitive quantitative determinations, metabolite identification and other complex analytical requests. Our immunology experts offer comprehensive analytical support for complex biologics, extensive immune monitoring capabilities, and the flexibility and knowledge to develop assays for new technologies. Our classically trained virology team, have a wealth of industry experience, have worked with most virus families known to science and add to the breadth and depth of BioAgilytix’s capabilities. We have the capacity to support bioanalysis for new and established small molecules, peptides, proteins and large molecules by offering services such as:
BioAgilytix has a team of exceptional biologists and chemists with global pharma and biotech industry experience and a proven track record of advancing therapeutic drugs, biomolecules and vaccines through clinical development.
We have the technical knowledge and experience to deliver accurate, reproducible and robust assay data which will progress your therapeutic through regulatory review. We are dedicated to providing a quality service that efficiently delivers results, and are proud of our reputation as a highly-skilled team with an agile and responsive approach to study management and communication.
Global BioAgilytix operates as One Team with One Mission, enabling the breakthroughs of tomorrow today.
BioAgilytix’s Brisbane laboratory is located in the Translational Research Institute (TRI). Co-located with the TRI Clinical Research Facility (CRF) at the Princess Alexandra Hospital (PAH) the facility provides state-of-the-art specialist facilities, resources and expertise for investigator led and commercially sponsored clinical trials. TRI is focused ‘bench to bedside’ on the effective translation of research and innovation into improved healthcare, consistent with our mission of enabling future medicines.
BioAgilytix’s Melbourne laboratory is located within the world-renowned Burnet Institute at the Alfred Hospital biomedical and clinical research precinct, also home to Australia’s largest Phase 1 unit. The Melbourne laboratory facilities are perfectly situated to benefit from the unique advantages of conducting studies in Australia.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St, Woolloongabba
Queensland, 4102, Australia
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 617-456-0700
37 Kent St,Woolloongabba
Queensland, 4102, Australia
1320 Soldiers Field Road
Boston, MA, 02135
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Lademannbogen 10
22339 Hamburg Germany
85 Commercial Road, Melbourne
Victoria, 3004, Australia
Copyright © 2022 BioAgilytix Labs.
All rights reserved.